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Aim: To describe the clinical characteristics and disease
course of a large family with retinitis pigmentosa (RP) from an
Arg135Leu change in rhodopsin.
Methods: 29 patients in this family were evaluated.
Goldmann visual fields were performed on 14 affected
individuals, Ganzfeld electroretinography (ERG) on eight
individuals (11–56 years), and blood samples collected on
10 individuals (11–58 years). Patient visual field data were
compared with previously reported patients with different
rhodopsin mutations using linear regression.
Results: An Arg135Leu mutation was identified in rhodopsin.
Distinct stages of clinical evolution were identified for this
family ranging from normal, white dots, classic bone spicules
and, finally, ending with extensive retinal pigment epithelium
(RPE) atrophy. 9/16 patients over the age of 20 years also
demonstrated marked macular atrophy. All patients who
underwent full field ERG testing demonstrated non-record-
able ERGs. The overall regression model comparing solid
angles of visual fields from patients with rhodopsin mutations
(Pro23His, Pro347Ala, Arg135Leu) shows significant effects
for age (p = 0.0005), mutation (p = 0.0014), and interaction
between age and mutation (p = 0.018) with an R2 of 0.407.
Conclusions: An Arg135Leu change in rhodopsin results in a
severe form of RP that evolves through various fundus
appearances that include white dots early in life and classic
appearing RP later. This transmembrane change in rhodop-
sin proves to be more severe than in a family with an
intradiscal change and a family with a cytoplasmic change.
R
etinitis pigmentosa (RP) is characterised by clinical
findings of bone spicules, arteriolar attenuation, and
optic nerve atrophy. However, there is a wide range of
presentation and severity. The clinical appearance of any
given patient with RP depends on the stage of the patient in
the disorder and the molecular basis of disease. Of the
approximately 100 000 patients with RP in the United States,
15–20% of patients have autosomal dominant retinitis
pigmentosa (ADRP).1–3 The most common molecular causes
of ADRP are changes in rhodopsin. Rhodopsin related RP
tends to have a milder disease course than other forms of
RP.1 4 However, Sandberg demonstrated that the severity of
rhodopsin related RP was dependent on the site of the
sequence variation.5 An Arg135Leu mutation in rhodopsin
was reported by Sung.4 6 7 We describe the clinical character-
istics of this mutation in a 13 generation family. This change
in rhodopsin demonstrates a very severe course with wide-
spread white dots early that fade into a more classic
appearance of RP in adulthood.
SUBJECTS AND METHODS
This study had approval of the institutional review board of
the University of North Carolina (UNC). A total of 24 affected
patients, all members of a 13 generation family with ADRP
(fig 1), were examined at UNC. Five additional affected and
multiple unaffected patients were examined at a family
reunion by the author. Patients clearly reported nyctalopia
from early childhood and this symptom was used to
determine disease status. Affected patients from four
different generations and two separate branches of the
family came to UNC. Patients underwent a standard eye
examination, Goldmann perimetry, electroretinographic test-
ing, and fundus photography. Patients with hand movement
or worse vision did not undergo ancillary testing. Full field
electroretinography and multifocal electroretinography
(mfERG) were performed according to ISCEV standards.8 9
Eight patients underwent full field ERG testing with an LKC
Veritas system (Gaithersburg, MD, USA). Three patients
underwent mfERG using a Veris system (ElectroDiagnostics,
Inc, San Mateo, CA, USA). Goldmann visual fields (GVF)
were converted to solid angle (in steradians) using described
methods.10 11 A linear regression model was performed from
patients with Arg135Leu, Pro23His and Pro347Ala mutations
in rhodopsin11 (JMP SAS, Cary, NC, USA).
Molecular analysis and findings
Ten patients at various disease stages ranging in age from 11–
58 years had blood samples sent to the Carver Molecular
Ophthalmology Laboratory for analysis. Screening using an
amplification refractory mutation system (ARMS)12 disclosed
neither the Pro23His nor Arg135Trp changes in rhodopsin.
Samples that had aberrant migration patterns of polymerase
chain reaction products, using single stranded conforma-
tional polymorphism analysis,11 13 14 were sequenced bidir-
ectionally with fluorescent dideoxynucleotides on an ABI
model 377 automated sequencer. An Arg135Leu change in
rhodopsin was identified in all samples.
RESULTS
Clinical findings
All affected patients in this study, ranging in age from 7–
64 years of age, reported symptoms of nyctalopia before
5 years of age. No unaffected patients demonstrated white
dots or other signs of RP. Visual acuity ranged from 20/20 to
light perception and remained stable until the development
of posterior subcapsular cataracts in the third to fourth
decade of life (fig 2). Nearly all patients over the age of 16
who were evaluated had cataracts or intraocular lenses with
maintained central visual acuity until the fourth to fifth
decade of life. However, 9/16 patients over the age of 20 years
demonstrated some degree of macular atrophy that com-
promised central vision (fig 3A). Six of seven patients under
the age of 20 years who were examined, demonstrated
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widespread white dots and minimal RPE changes with only
the youngest patient (age 7 years) not demonstrating any
definite signs (fig 3B and 3C). In the second to third decades,
the white dots fade and are replaced by RPE atrophy and
bone spicules (fig 3D) and, finally, the fundus shows marked
RPE atrophy and choroidal sclerosis (fig 3E and F).
Electroretinographic findings
We evaluated eight patients with full field electroretinogra-
phy (ages 11–50 years) and three patients with mfERG. All
patients undergoing full field electroretinography showed
non-recordable responses. For mfERG testing, only the
16 year old demonstrated recordable retinal function, though
no other patients younger than 40 years were tested. Repeat
mfERG for this patient 13 months later found considerable
further loss of recordable amplitude.
Perimetric findings
Fifteen patients underwent Goldmann perimetry. There was
no measurable field with the I4e isoptre by the fourth decade
of life. The V4e test target became undetectable by the sixth
decade of life (fig 4). When the solid angle of I4e isoptre was
compared to the clinical characteristics of the Pro23His and
the Pro347Ala change in rhodopsin, there was a significant
difference in the loss of visual field for patients with an
Arg135Leu change in rhodopsin compared with the other
mutations. The difference between visual field data for
patients with the rhodopsin Arg135Leu RP and those with
either other change remained significant at the 0.0005 level
after Bonferroni correction (fig 5). The overall regression
model comparing patients with rhodopsin mutations
(Pro23His, Pro347Ala, Arg135Leu) shows significant effects
for age (p=0.0005), mutation (p=0.0014), and interaction
between age and mutation (p=0.018) with an R2 of 0.407.
Comparison of Arg135Leu change and Pro23His change
demonstrated a significant difference in these populations
(p=0.0002) but no significance in the effect of age or the
interaction of age and mutation. Comparison of Arg135Leu
change and Pro347Ala change shows significant effect of age
(p=0.0001), mutation (p=0.0001), and the interaction of
age with mutation (p=0.0003).
DISCUSSION
Rhodopsin related disease may present with a wide spectrum
of severity and clinical features, including regional and
diffuse RP,15–17 sectoral RP,18–23 and congenital stationary
night blindness.24–27 Sandberg previously identified the
importance of the locus of mutations in rhodopsin to a
specific patient’s disease course, showing that intradiscal
variations such as Pro23His carried the mildest course of
disease and cytoplasmic variations such as at codon 347
carried the most severe prognosis.5 28 The severity of muta-
tions in the intracytoplasmic region of rhodopsin is well
documented though only a few clinical studies exist for
changes in the transmembrane region.29
Pannarale described one family with an Arg135Trp muta-
tion in rhodopsin with a very severe course. That family
demonstrated non-recordable electroretinographic responses
by the third decade of life but low, recordable wave forms for
younger patients.17 Thus, changes associated with codon 135
may result in a more severe course.30 The appearance of white
dots in association with rhodopsin and, specifically,
Arg135Trp rhodopsin related RP, was described by Souied
as an early finding in that form of RP.31 The term retinitis
punctata albescens (RPA) was originally used to denote a
specific form of RP.32 Although some have questioned in the
Figure 1 Pedigree. The family, which clearly demonstrates an autosomal dominant pattern of inheritance, could be traced back 13 generations. The
branches of the family that participated in the current study are boxed. From the left box, one woman from generation X, five patients from generation
XI, and two patients from generation XII were examined. From the right box, seven patients from generation XI, seven patients from generation XII, and
two patients from generation XIII were examined at UNC. The majority of living affected and unaffected members of these two branches of the family
were examined at the family reunion in western North Carolina.
Figure 2 Visual acuity. The central visual acuity of the better seeing eye
of each patient is plotted against their age at examination. From this
distribution, there is a notable drop off in central visual acuity by the
fourth decade of life. Outliers who maintain central visual acuity beyond
the fourth decade of life notably have minimal macular atrophy.
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past whether RPA was a specific disorder or simply a
phenotype or stage of classic RP,33 recently, RPA has been
recognised as a specific autosomal recessive retinal degenera-
tion that results from mutations in the gene RLBP1.34–36
Admittedly, though, the white dots in RPA, although similar,
are clinically different from those observed in our family.
In summary, we present a family with RP caused by an
Arg135Leu mutation in rhodopsin. This family demonstrated
a particularly severe course that was worse than families with
cytoplasmic or intradiscal mutations in rhodopsin. From a
cross sectional study of patients, we inferred the progression
of disease for this family. In the first decade of life, affected
patients will be symptomatic without clinical signs on fundus
examination. By the second decade, patients develop
extensive fine white dots at the level of the retinal pigment
epithelium in the absence of extensive RPE atrophy or bone
spicules. The white dots fade by the third decade of life
leaving bone spicules with widespread RPE atrophy. This
appearance steadily worsens with increasing age and is
associated with progressive decrease in visual field area.
Patients uniformly developed cataracts by the second decade
of life and appeared to respond favourably to cataract
extraction. However, macular atrophy, as observed in our
patients, is not uncommon in patients with changes at codon
135 of rhodopsin.7 17 30 Central acuity appeared to be closely
related to the degree of macular atrophy.17
Description of disease natural history is becoming increas-
ingly important with the future of hereditary retinal
degenerations directed towards intervention. This family
demonstrates how a specific phenotype may be present only
for a brief period in a patient’s life. While this is not the first
paper to describe the association of a white dot phenotype
Figure 3 Fundus appearance. (A) Fundus image of affected man, aged 41 years. Note the parafoveal atrophy of the retinal pigment epithelium (RPE).
There is RPE atrophy and bone spicules beyond the arcades. Arterioles are attenuated. (B) Fundus image of affected boy, aged 9 years. Note the
relative lack of fundus findings. This patient has some pallor to the optic nerve and attenuation of his arterioles. Periphery demonstrated no evidence of
RPE atrophy, bone spicules, or white dots. (C) Fundus image of affected girl, aged 11. Note the extensive white dots and RPE mottling in the mid-
periphery. Bone spicules are notably absent. (D) Fundus image of affected girl, aged 16. Note the presence of white dots and RPE atrophy. Bone
spicules are beginning to develop in the mid-periphery. (E) Fundus image of affected woman, aged 45 years. Note the extensive RPE thinning and
atrophy both in the mid-periphery and the macula. The optic nerve is pale and there is arteriolar attenuation. (F) Fundus image of affected man, aged
57 years. Note the extensive RPE clumps in the mid-periphery and visible sclerotic choroidal vessels.
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with rhodopsin, we are the first to clearly document that this
clinical appearance is largely dependent on the age of the
subject. We also further demonstrated the importance of age
and genotype for the modelling of disease course as
previously described.37 The R2 value predicts that up to
40.7% of disease variation may be predicted on the basis of
patient age and specific genotype. While other factors will
influence disease course, this value calls attention to the
importance of these two variables. The severity of this
particular form of retinitis pigmentosa and the careful
understanding of its natural history will be important
considerations in the inclusion of patients with this condition
in future clinical trials.
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